再鼎医药今日盘中股价大跌5.68%，引发了市场广泛关注。
消息面上，公司此前发布的2026年第一季度业绩报告表现疲软。报告显示，公司第一季度总收入约为9960万美元，同比下降约6%；产品收入净额同比下降约10%，若按固定汇率计算则下降12%。同时，公司亏损净额扩大至约5100万美元，较上年同期有所增加。
业绩下滑的主要原因包括核心产品“则乐”面临市场竞争影响，以及“卫伟迦”因与国家医保目录续约而进行价格调整。此外，公司的研发开支有所增加，进一步加剧了亏损。这份不及预期的财报导致市场对公司短期基本面承压的预期升温，从而拖累了股价表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.